AR085928A1 - COMBINED THERAPY TO TREAT HCV INFECTIONS (HEPATITIS C VIRUSES) IN A SUBPOBLATION OF SPECIFIC PATIENT SUBGENOTYPES - Google Patents
COMBINED THERAPY TO TREAT HCV INFECTIONS (HEPATITIS C VIRUSES) IN A SUBPOBLATION OF SPECIFIC PATIENT SUBGENOTYPESInfo
- Publication number
- AR085928A1 AR085928A1 ARP120101145A AR085928A1 AR 085928 A1 AR085928 A1 AR 085928A1 AR P120101145 A ARP120101145 A AR P120101145A AR 085928 A1 AR085928 A1 AR 085928A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- snp
- genotype
- pharmaceutically acceptable
- hepatitis
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables, en donde: B es un resto de fórmula (2); L0 es MeO-; L1 es Br; y R2 es un resto de fórmula (3); para usar en un método de tratamiento de infección viral por hepatitis C (HCV) o alivio de uno o varios de sus síntomas en un paciente que tiene un genotipo no CC de SNP rs12979860 o un genotipo no TT de SNP rs 8099917 ubicado cerca del gen IL-28B, donde dicho método comprende la administración al paciente: (a) el compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables; (b) interferón a; y (c) ribavirina.Reivindicación 30: Una composición farmacéutica envasada que comprende un envase que contiene: (a) una o varias dosis de la fórmula (1) o una de sus sales farmacéuticamente aceptables, en donde: B es un resto de fórmula (2); L0 es MeO-; L1 es Br; y R2 es el resto de fórmula (3); y (b) instrucciones escritas referidas a la coadministración del compuesto de fórmula (1), o una de sus sales farmacéuticamente aceptables, interferón a y ribavirina para el tratamiento de infección por HCV en un paciente que tiene un genotipo no CC de SNP rs12979860 o un genotipo no TT de SNP rs 8099917 ubicado cerca del gen IL-28B.Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein: B is a residue of formula (2); L0 is MeO-; L1 is Br; and R2 is a residue of formula (3); for use in a method of treating hepatitis C viral infection (HCV) or relief of one or more of its symptoms in a patient who has a non-CC genotype of SNP rs12979860 or a non-TT genotype of SNP rs 8099917 located near the gene IL-28B, wherein said method comprises administration to the patient: (a) the compound of the formula (1) or a pharmaceutically acceptable salt thereof; (b) interferon a; and (c) ribavirin. Claim 30: A packaged pharmaceutical composition comprising a package containing: (a) one or several doses of the formula (1) or one of its pharmaceutically acceptable salts, wherein: B is a remainder of the formula (2); L0 is MeO-; L1 is Br; and R2 is the remainder of formula (3); and (b) written instructions regarding the co-administration of the compound of formula (1), or a pharmaceutically acceptable salt thereof, interferon a and ribavirin for the treatment of HCV infection in a patient who has a non-CC genotype of SNP rs12979860 or a non-TT genotype of SNP rs 8099917 located near the IL-28B gene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP120101145 AR085928A1 (en) | 2012-04-03 | 2012-04-03 | COMBINED THERAPY TO TREAT HCV INFECTIONS (HEPATITIS C VIRUSES) IN A SUBPOBLATION OF SPECIFIC PATIENT SUBGENOTYPES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP120101145 AR085928A1 (en) | 2012-04-03 | 2012-04-03 | COMBINED THERAPY TO TREAT HCV INFECTIONS (HEPATITIS C VIRUSES) IN A SUBPOBLATION OF SPECIFIC PATIENT SUBGENOTYPES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085928A1 true AR085928A1 (en) | 2013-11-06 |
Family
ID=50190002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101145 AR085928A1 (en) | 2012-04-03 | 2012-04-03 | COMBINED THERAPY TO TREAT HCV INFECTIONS (HEPATITIS C VIRUSES) IN A SUBPOBLATION OF SPECIFIC PATIENT SUBGENOTYPES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR085928A1 (en) |
-
2012
- 2012-04-03 AR ARP120101145 patent/AR085928A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012022311A2 (en) | combination pharmaceutical agents as inhibitors of hcv replication. | |
| CL2011000571A1 (en) | Use of a combination of: a) a compound of formula (1) or a pharmaceutically acceptable salt thereof, b) interferon alfa and c) ribavirin to prepare a medicament useful for the treatment of a viral infection of hepatitis c (hcv) or to relieve one or more symptoms of it. | |
| EA201200096A1 (en) | PHARMACEUTICAL COMPOSITION OF THE HYPATITIS VIRUS PROTEASE INHIBITOR INHIBITOR | |
| RU2013119607A (en) | POLYCYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR APPLICATION FOR TREATMENT OF VIRAL DISEASES | |
| CU20150096A7 (en) | AMIDA COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR HIV TREATMENT | |
| RU2014122154A (en) | COMPOSITIONS SUITABLE FOR THE TREATMENT OF VIRAL DISEASES | |
| RU2015114543A (en) | HEPATITIS TREATMENT METHODS | |
| CL2012001449A1 (en) | Use of combinations of the compound n - [(cyclopentyloxy) carbonyl] -3-methyl-l-valiol- (4r) -4 - ({8-bromo-2- [2- (isobutyrylamino) -1,3-thiazole-4 -yl] -7-methoxy-4-quinolinyl} oxy) -n - [(1r, 2s) -1-carboxy-2-vinylcyclopropyl] -l-prolinamide; and container comprising the dosage forms. | |
| SI2709613T1 (en) | Methods for treating hcv | |
| CL2013003360A1 (en) | "4-aryl-n- [3- (sulfonimidoyl) phenyl] -1,3,5-triazin-2-amine substituted compounds, cdk inhibitors; intermediary compounds, composition and pharmaceutical combination comprising them; and its use in the treatment of hyperproliferative, infectious diseases induced by viruses and / or cardiovascular diseases ”. pct | |
| JP2011528713A5 (en) | ||
| UY33897A (en) | HEPATITIS C VIRUS INHIBITORS | |
| ECSP14013189A (en) | INHIBITORS OF THE REPLICATION OF VIRUSES OF THE FLU | |
| EA201490419A1 (en) | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCIAL VIRAL DISEASE | |
| MY202109A (en) | Viral replication inhibitors | |
| BRPI0511283A (en) | substituted aryl acylthioureas and related compounds; viral replication inhibitors | |
| CR20140086A (en) | COMBINATION TREATMENTS FOR HEPATITIS C | |
| EA201991174A1 (en) | COMBINATION OF TWO ANTIVIRAL DRUGS FOR TREATMENT OF HEPATITIS C | |
| AR062453A1 (en) | METHOD OF COMBINED THERAPY FOR THE TREATMENT OF INFECTION BY THE VIRUS OF HEPATITIS C AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SUCH THERAPY | |
| BR112013028679A2 (en) | hepatitis c virus inhibitors | |
| JO3281B1 (en) | Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections | |
| ECSP13012551A (en) | COMBINATION THERAPY TO TREAT HCV INFECTION. | |
| EA201170484A1 (en) | THERAPEUTIC MODE OF HEPATITIS TREATMENT, INCLUDING PEG-INTERFERON, RIBAVIRIN AND VX-950 | |
| EA201170605A1 (en) | CYCLONE DECADEPSYPE COMPOUNDS AND APPLICATION OF THE SPECIFIED COMPOUNDS AS A MEDICINE | |
| AR088204A1 (en) | MEDICINES FOR THE TREATMENT OF ALLERGY RHINITIS THAT INCLUDE A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |